help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TAN, K. S.
Right arrow Articles by LIPWORTH, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TAN, K. S.
Right arrow Articles by LIPWORTH, B. J.

Am. J. Respir. Crit. Care Med., Volume 156, Number 1, July 1997, 28-35

Systemic Corticosteriod Rapidly Reverses Bronchodilator Subsensitivity Induced by Formoterol in Asthmatic Patients

KIA SOONG TAN, ALISON GROVE, ALEC MCLEAN, YVONNE GNOSSPELIUS, IAN P. HALL, and BRIAN J. LIPWORTH

Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland; Astra Draco, Lund, Sweden; and Department of Medicine, University Hospital of Nottingham, Nottingham, United Kingdom

There is evidence that downregulation and desensitization of airway beta 2-adrenoceptors (beta 2-AR) develops after continuous exposure to long-acting beta 2-agonists such as formoterol and salmeterol. To investigate the facilitatory effects of acute administration of systemic corticosteroid on bronchodilator subsensitivity, as might occur in the setting of acute asthma, 12 subjects with moderately severe asthma, with a mean FEV1 of 66% predicted, of whom were all receiving inhaled corticosteriod, were randomized to receive either inhaled placebo (PL) or inhaled formoterol (FM) 24 µg twice daily for 4 wk in a double-blind crossover study. Subjects were also genotyped in terms of beta 2-AR polymorphism at loci 16 and 27. A dose-response curve (DRC) and duration-time profile for FM (12 to 108 µg) was produced 1 h after administration of placebo tablets and after injection at 3 wk, and 1 h after administration of oral prednisolone, 50 mg, and intravenous hydrocortisone, 200 mg, at 4 wk. Comparisons between treatments were made with area-under-curve (AUC) measurements as the change from baseline. There was a significant rightward shift in the DRC after FM as opposed to placebo for Delta FEV1 (as AUC, L · h): 2.51 versus 4.22 (95% CI: 0.54 to 2.89; p = 0.01) and Delta FEF25-75 (as AUC, L × 103): 11.30 versus 19.94 (95% CI: 2.12 to 15.12; p = 0.01). This was significantly reversed by steroid (S) for FEV1 (FM versus FM + S): 2.51 versus 3.57 (95% CI: 0.11 to 2.27; p = 0.03) and for FEF25-75: 11.30 versus 18.47 (95% CI: 2.52 to 11.70; p = 0.005). Lymphocyte beta 2-AR density (log Bmax; fmol/106 cells) showed significant upregulation 3 h after steroid (FM + S versus FM): 0.34 versus 0.24 (95% CI: 0.02 to 0.18; p = 0.01). For heart-rate response (as AUC, beats), there was subsensitivity with FM versus PL: 2,700 versus 5,200 (95% CI: 40 to 5,000; p < 0.001), and this was reversed by steroid (FM + S versus FM): 9,600 versus 2,700 (95% CI: 4,900 to 8,800; p < 0.001). This reversal by systemic corticosteroid appears to be generally independent of beta 2-AR polymorphism at loci 16 and 27. In conclusion, we have demonstrated that bronchodilator subsensitivity occurs after regular inhaled FM in asthmatic patients, and is rapidly reversed by systemic corticosteroid. Thus, in acute asthma, systemic corticosteroid should be administered a soon as possible, in order to restore normal airway beta 2-AR sensitivity, particularly in patients who are receiving regular long-acting beta 2-agonists.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Jaeschke, P. M. O'Byrne, F. Mejza, P. Nair, W. Lesniak, J. Brozek, L. Thabane, J. Cheng, H. J. Schunemann, M. R. Sears, et al.
The Safety of Long-Acting {beta}-Agonists among Patients with Asthma Using Inhaled Corticosteroids: Systematic Review and Metaanalysis
Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1009 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
H. K. Reddel and D. J. Barnes
Pharmacological strategies for self-management of asthma exacerbations.
Eur. Respir. J., July 1, 2006; 28(1): 182 - 199.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma
Ann Intern Med, May 18, 2004; 140(10): 802 - 813.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
H. Kume, T. Ishikawa, T. Oguma, S. Ito, K. Shimokata, and M. I. Kotlikoff
Involvement of Ca2+ Mobilization in Tachyphylaxis to {beta}-Adrenergic Receptors in Trachealis
Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): 359 - 366.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
G.P. Currie, C.M. Jackson, S.A. Ogston, and B.J. Lipworth
Airway-stabilizing effect of long-acting {beta}2-agonists as add-on therapy to inhaled corticosteroids
QJM, June 1, 2003; 96(6): 435 - 440.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J.M. Wraight, R.J. Hancox, G.P. Herbison, J.O. Cowan, E.M. Flannery, and D.R. Taylor
Bronchodilator tolerance: the impact of increasing bronchoconstriction
Eur. Respir. J., May 1, 2003; 21(5): 810 - 815.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. Kanazawa, T. Mamoto, K. Hirata, and J. Yoshikawa
Interferon Therapy Induces the Improvement of Lung Function by Inhaled Corticosteroid Therapy in Asthmatic Patients With Chronic Hepatitis C Virus Infection*: A Preliminary Study
Chest, February 1, 2003; 123(2): 600 - 603.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. Brichetto, M. Milanese, P. Song, M. Patrone, E. Crimi, K. Rehder, and V. Brusasco
Beclomethasone rapidly ablates allergen-induced beta 2- adrenoceptor pathway dysfunction in human isolated bronchi
Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L133 - L139.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. J. Vanacker, E. Palmans, R. A. Pauwels, and J. C. Kips
Effect of Combining Salmeterol and Fluticasone on the Progression of Airway Remodeling
Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1128 - 1134.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
F M Spoelstra, D S Postma, H Hovenga, J A Noordhoek, and H F Kauffman
Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts
Thorax, March 1, 2002; 57(3): 237 - 241.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
H J van der Woude, T H Winter, and R Aalbers
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists
Thorax, July 1, 2001; 56(7): 529 - 535.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S.L. Jones, J.O. Cowan, E.M. Flannery, R.J. Hancox, G.P. Herbison, and D.R. Taylor
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Eur. Respir. J., March 1, 2001; 17(3): 368 - 373.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D.C. Grootendorst, P.J. Sterk, and H.G.M. Heijerman
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Eur. Respir. J., March 1, 2001; 17(3): 374 - 379.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Noseda, I. De Bruyne, V. De Maertelaer, and J.-C. Yernault
Does an IV Bolus of Methylprednisolone Relieve Dyspnea in Asthma Exacerbations?
Chest, December 1, 2000; 118(6): 1530 - 1537.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. J. Lipworth, O. J. Dempsey, and I. Aziz
Functional Antagonism With Formoterol and Salmeterol in Asthmatic Patients Expressing the Homozygous Glycine-16 {beta}2-Adrenoceptor Polymorphism
Chest, August 1, 2000; 118(2): 321 - 328.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D R Taylor and R J Hancox
Interactions between corticosteroids and beta agonists
Thorax, July 1, 2000; 55(7): 595 - 602.
[Full Text]


Home page
ThoraxHome page
R J Dockhorn, R A Baumgartner, J A Leff, M Noonan, K Vandormael, W Stricker, D E Weinland, and T F Reiss
Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients
Thorax, April 1, 2000; 55(4): 260 - 265.
[Abstract] [Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
G. P. ANDERSON
Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation
Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S188 - 196.
[Full Text] [PDF]


Home page
ChestHome page
B. J. Lipworth and I. Aziz
Bronchodilator Response to Albuterol After Regular Formoterol and Effects of Acute Corticosteroid Administration*
Chest, January 1, 2000; 117(1): 156 - 162.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page

Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 2125 - 2126.
[Full Text]


Home page
ChestHome page
G. Rodrigo and C. Rodrigo
Corticosteroids in the Emergency Department Therapy of Acute Adult Asthma: An Evidence-Based Evaluation
Chest, August 1, 1999; 116(2): 285 - 295.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
I. Aziz and B. J. Lipworth
A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitivity and {beta}2-Adrenoceptor Down-regulation After Regular Inhaled Formoterol
Chest, March 1, 1999; 115(3): 623 - 628.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. CHEUNG, A. M. J. WEVER, J. A. de GOEIJ, C. S. de GRAAFF, H. STEEN, and P. J. STERK
Effects of Theophylline on Tolerance to the Bronchoprotective Actions of Salmeterol in Asthmatics In Vivo
Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 792 - 796.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. J. BARNES, S. PEDERSEN, and W. W. BUSSE
Efficacy and Safety of Inhaled Corticosteroids . New Developments
Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society
  ATS Clinical Skills Tests